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Pharmacological inhibition of the renin–angiotensin–aldosterone system (RAAS) is, in 
combination with diuretics, the first-choice treatment for hypertension, although 10–20% 
of patients do not respond adequately. Next to the RAAS, the nitric oxide/cGMP/protein 
kinase G (PKG) system is the second fundamental blood pressure regulator. Whether 
both systems influence each other is not well-studied. It has been shown that nitric oxide 
(NO) supports renin recruitment via activation of soluble guanylate cyclase (sGC) and 
subsequent generation of cGMP. Whether this leads to an ensuing activation of PKGs 
in this context is not known. PKGIα, as well as PKGII, is expressed in renin-producing 
cells. Hence, we analyzed whether these enzymes play a role regarding renin synthesis, 
secretion, or recruitment. We generated renin-cell-specific PKGI-knockout mice and 
either stimulated or inhibited the renin system in these mice by salt diets. To exclude the 
possibility that one kinase isoform can compensate the lack of the other, we also studied 
double-knockout animals with a conditional knockout of PKGI in juxtaglomerular cells 
(JG cells) and a ubiquitous knockout of PKGII. We analyzed blood pressure, renin mRNA 
and renal renin protein content as well as plasma renin concentration. Furthermore, we 
stimulated the cGMP system in these mice using BAY 41-8543, an sGC stimulator, and 
examined renin regulation either after acute administration or after 7 days (application 
once daily). We did not reveal any striking differences regarding long-term renin regulation 
in the studied mouse models. Yet, when we studied the acute effect of BAY 41-8543 on 
renin secretion in isolated perfused kidneys as well as in living animals, we found that the 
administration of the substance led to a significant increase in plasma renin concentration 
in control animals. This effect was completely abolished in double-knockout animals. 
However, after 7 days of once daily application, we did not detect a persistent increase 
in renin mRNA or protein in any studied genotype. Therefore, we conclude that in mice, 
cGMP and PKG are involved in the acute regulation of renin release but have no influence 
on long-term renin adjustment.
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INTRODUCTION
The NO/cGMP system and the renin–angiotensin–aldosterone 
system (RAAS) are both crucial players in blood pressure (BP) 
regulation and can be seen as two scale pans in BP balance. 
While NO/cGMP acts vasodilatory via different mechanisms 
(reviewed in Thoonen et al., 2013), the RAAS is essential for an 
upregulation of BP. The juxtaglomerular cells (JG cells) are the 
exclusive site for secretion of renin in the kidney and consists 
of myofibroblast-like cells that are located in the media layer 
of vasa afferentia at the entrance into the glomerulus. Because 
renin is the key enzyme in the RAAS, the regulation of renin 
secretion is of great importance in the regulation of this system 
and occurs, on the one hand, via on-/offset of renin synthesis 
and, on the other hand, via control of renin secretion. Moreover, 
during chronic challenges of the RAAS, the kidney reacts via 
hypertrophy of juxtaglomerular cells and via transformation 
of preglomerular vascular smooth muscle cells (VSMCs) into 
renin-producing cells, the so-called “renin recruitment” (Owen 
et al., 1995; Sequeira López, et al., 2004). Because upregulation 
of plasma renin concentration (PRC) leads to hypertension and 
organ damage in humans, it would be of great importance to 
understand the underlying signaling mechanisms that trigger 
renin synthesis, secretion, and recruitment. cAMP is one of 
the best investigated second messengers in this context. This 
molecule plays a fundamental role in control points of renin 
activity regarding regulation of renin gene transcription and 
renin secretion. Regarding modulation of renin synthesis, it is 
commonly accepted that transcriptional regulation via different 
regions within the renin gene is the most essential step (Pan and 
Gross, 2005; Martinez et al., 2018). Among others, the cAMP/
CRE/CREB system is an important transcription factor system 
involved in renin gene regulation (Pan et al., 2001). Next to 
cAMP, the cGMP signaling pathway is also indispensable for 
gene regulations. Recently, it has been shown that cGMP-
dependent protein kinase Iα (PKGIα) mediates GATA4 
(a transcription factor which is important for cardiac development 
and diseases) transcriptional activity by phosphorylation and 
physical association of both interaction partners (Ma et al., 
2016). Whether cGMP/PKG also affects renin gene transcription 
is only partially characterized so far (Wagner et al., 1998).
The next step in renin synthesis following transcription and 
translation is the maturation of preprorenin to prorenin, which is 
then sorted in the Golgi apparatus and either directly released into 
circulation or further processed to the enzymatically active renin. 
For that to happen, glycosylation steps are necessary, which in 
turn lead to a direction of glycosylated prorenin into the vesicular 
network in the JG cell. A final proteolytic cleavage gives rise to 
mature renin, a protein with a molecular mass of around 36 kDa, 
which is then stored in intracellular vesicles until the cell obtains a 
release signal (Yokosawa et al., 1980). The underlying mechanisms 
of these processes as well as the identity of the protease responsible 
for renin activation still remain unclear (Gross et al., 2010).
Renin secretion occurs in response to various signals, e.g., 
catecholamines or prostaglandins, and is basically mediated through 
an increase in cAMP (likely by subsequent activation of PKA) 
(Friis et al., 2002). However, contradictory data were published 
concerning nitric oxide (NO) and thus cGMP involvement in renin 
secretion. In the 1990s, NO was thought to inhibit renin release 
(Beierwaltes and Carretero, 1992; Salazar et al., 1992; Sigmon et al., 
1992). Later, more and more convincing evidence was supplied, 
which supports the view that the NO/cGMP system is a positive 
regulator of renin secretion (Tharaux et al., 1997; Beierwaltes, 2006; 
Schnermann and Briggs, 2012). Moreover, NO, its intracellular 
receptor soluble guanylate cyclase (sGC), and cGMP have a 
prominent role in renin recruitment: in 2013, Neubauer et al. 
showed that endothelial NO synthase (eNOS)-produced NO 
supports renin cell recruitment and, more prominent, that this 
process is dependent on cGMP generated by sGC (Neubauer et al., 
2013). To date, four different effectors for cGMP are known: cyclic 
nucleotide gated channels (CNG channels), phosphodiesterases 
(PDEs), the multidrug resistance protein 4 (MRP4), which 
transports cGMP/cAMP out of the cells (van Aubel et al., 2002), 
and cGMP-dependent protein kinases (PKGs). In JG cells, it is 
known that cGMP interferes with cAMP degradation by inhibition 
of phosphodiesterase 3 (PDE3), thereby enabling cGMP/cAMP 
crosstalk. The subsequent increase in cAMP concentration leads 
to exocytosis of renin storage granula so that NO/cGMP indirectly 
supports renin secretion via PDE (Kurtz et al., 1998; Beierwaltes, 
2006; Sällström et al., 2010). Whether PKGs also take part in this 
regulation or if they can mediate renin cell recruitment is not 
known. These kinases exist in three isoforms: PKGIα, PKGIβ, and 
PKGII (Pfeifer et al., 1999). PKGIα and β are expressed from the 
same gene and differentiated through alternative splicing and are 
localized in the cellular cytoplasm (Wernet et al., 1989). Besides the 
investigation of expression patterns in other tissues (summarized 
in Geiselhöringer et al., 2004), we focused on renal distribution 
of PKGI in the past years and detected, next to other kidney 
parts, a prominent expression of PKGIα (but not PKGIβ) in the 
juxtaglomerular cell (Schinner et al., 2013). In the present study, we 
tested the hypothesis, whether this kinase is also involved in renin 
regulation. As experiments with global PKGI-knockout animals are 
rather difficult due to their reduced life span and severe phenotype 
including elevated blood pressure (Pfeifer et al., 1998), we generated 
renin-cell-specific conditional PKGI-knockout mice to address the 
function of this kinase regarding renin regulation. Next to PKGIα, 
PKGII is also expressed in JG cells; former reports suggested that 
renin secretion is inhibited by PKGII (Gambaryan et al., 1996; 
Wagner et al., 1998). To rule out the possibility that one kinase can 
compensate the lack of the other, we also conducted experiments 
with animals missing both kinases (global PKGII knockout, renin-
specific PKGI knockout). By administration of different salt diets 
as well as ACE inhibition by enalapril, we challenged the RAAS 
in these animals and checked the capability of the system to react 
to these stimuli. Furthermore, we stimulated the cGMP system by 
Bay 41-8543, an sGC stimulator, to study the effect of cGMP kinase 
deletion on the renin system.
MATERIAL AND METHODS
Animals
All animal experiments were performed in accordance with the 
Guidelines for the Care and Use of Laboratory Animals published 
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by the US National Institutes of Health and approved by the local 
authorities for animal research (Regierung von Unterfranken, 
D-97064 Würzburg, Germany; #RUF-55.2-2532-2-515-21). 
Renin cell-specific PKGI knockouts were derived from crossings 
of mice bearing a heterozygous insertion of Cre recombinase 
in the Ren1d gene locus (Ren1dCre/+) on a 129SVxC57/Bl6 
background [kindly provided by ML Sequeira López and 
R. Ariel Gomez (Sequeira López, et al., 2004)] and mice carrying 
a floxed exon 10 of the PKGI-gene (PKGIfl/fl) (Wegener et al., 
2002). Crossing of these mice resulted in Ren1dCre/+-PKGIflfl− 
animals (considered as Ren-PKGI-KO). Ren1d+/+-PKGIfl/
fl animals were considered as controls (hereinafter referred to 
as Ctr). The Ren1d+/+-PKGIfl/fl or Ren1dCre/+-PKGIfl/fl animals 
were crossed with PKGII-knockout mice (Pfeifer et al., 1996) 
to obtain finally either PKGI fl/fl/PKGII −/− (considered as 
PKGII-KO) or Ren-Cre/PKGI fl/fl/PKGII −/− (considered as 
Ren-PKGI-KO/PKGII-KO) animals. Genotyping was performed 
by PCR on DNA isolated from tail or ear biopsies (Renin-Cre: 
mRen-Ren: 5’-GAAGGAGAGCAAAAGGTAAGAG-3’, mRen 
Cre: 5’-TTGGTGTACGGTCAGTAAATTGGAC-3’; PKGI- 
flox: RF125: 5’-GTCAAGTGACCACTATG-3’, RF53: 5’-CCTGG 
CTGTGATTTCACTCCA-3’; PKGII-KO: AV3R: 5’-ATTAAGG 
GCCAGCTCATTCC-3’, AV9R: 5’-CTGCTTAATGACGTAG 
CTGCC-3’, E2FBAV: 5’-GGTGAAGTTTTAGGTGAAACCAA 
G-3’). Experimentation was conducted in male 8–40-week-
old mice and litter-matched controls. Mice were housed in 
a 12:12-h light–dark cycle and kept on standard rodent chow 
with free access to tap water. In addition, for stimulation of 
renin recruitment, mice were either receiving low salt diet (LS, 
0.03% NaCl; Ssniff, Germany) for 10 days or LS+enalapril (LS/
Ena, 10 mg/kg/day in drinking water; Sigma-Aldrich, Munich, 
Germany) for 3 weeks. To inhibit RAAS, mice were kept on 
high salt chow (HS; 4% NaCl; Ssniff, Germany) for 3 weeks. For 
stimulation of cGMP signaling, BAY 41-8543 was administered 
i.p. for either 45 min or for 7 consecutive days once daily [1 mg/
kg/day, dissolved in vehicle (0.6 g glycerol/1 g H2O/9.49 g PEG 
400); Bayer Pharma AG, Wuppertal, Germany]. Mice receiving 
only vehicle served as controls.
Blood Pressure Measurement
Systolic blood pressure of conscious mice was determined by 
tail cuff plethysmography (IITC Life Science, Woodland Hills, 
USA). Mice were trained for at least 3 consecutive days; after that, 
approximately 30 measurements were recorded, and values were 
averaged over 5–10 representative readings.
Isolated-Perfused Kidney
Kidneys of mice of different genotypes were perfused ex situ 
at a constant perfusion pressure (100 mmHg) as described 
previously (Schweda and Kurtz, 2004). The basic perfusion 
medium contained a modified Krebs–Henseleit buffer 
supplemented with BSA (6 g/100 ml) and human erythrocytes 
(10% hematocrit). The renal vein was cannulated, and the 
perfusate flowrate was allowed to stabilize for about 15 min. 
Then, increasing concentrations of Bay 41-8543 (10 nM, 100 
nM, 1 µM), 10 µM S-Nitroso-N-acetyl-D,L-penicillamine 
(SNAP, Cayman Chemical, Ann Harbor, USA) and finally 
10  nM isoproterenol (positive control, Cayman Chemical, 
Ann Harbor, USA) were added to the perfusate. Samples of the 
venous perfusate were collected every 2 min to determine renal 
blood flow and renin secretion rate, which was calculated as 
the product of renin activity [determined by enzyme-linked 
immunosorbent assay (ELISA), see below] and the venous 
flowrate [ng angI/(h*ml) per g kidney weight]. Renin secretion 
rate after Bay or SNAP treatment was then conclusively related 
to renin secretion rate obtained after isoproterenol treatment.
Quantitative mRNA Analysis
Following salt treatment, the left kidney was excised and halved, 
stored overnight in a fridge in RNAlater (ThermoScientific, 
Braunschweig, Germany) for penetration into tissue, and then 
transferred into −80°C until further processing. Total RNA was 
isolated from the kidney using the PeqGOLD TriFast™ reagent 
(PeqLab, Erlangen, Germany) for phenol/chloroform extraction. 
After determination of concentration and quality control, 2 µg 
RNA was reverse transcribed (0.5 µg oligo-dT-Primer, 200 U 
M-MLV-RT, 20 U RNAsin) and 2 µl cDNA were assayed for renin 
(forward: 5’-ATGAAGGGGGTGTCTGTGGGGTC-3’, reverse: 
5’-ATGCGGGGAGGGTGGGCACCTG-3’) and GAPDH as 
housekeeper (forward: 5’-CACCAGGGCTGCCATTTGCA-3’, 
reverse: 5’-GCTCCACCCTTCAAGTGG-3’) using the Roche 
LightCycler 480 system with SYBR green I (Roche, Mannheim, 
Germany) as fluorescent dye. For relative quantification, the 
∆∆Ct method was used.
Western Blot Analysis
Proteins were extracted from whole kidneys in 2% lubrol (20 mM 
Tris, 140 mM NaCl, 2% nonaethylenglycolmonodecylether, 1 mM 
benzamidine, 0.5 µg/µl leupeptin, 0.3 mM PMSF, PhosStop, pH = 
8.0) using an ultraturrax, and 50–70 µg of total protein was loaded 
on each lane. Following 11.5–12% SDS-PAGE, proteins were blotted 
on a polyvinylidine fluoride (PVDF) membrane and incubated 
with renin antibody (R&D systems, Wiesbaden-Nordenstadt, 
Germany). Vinculin (R&D systems, Wiesbaden-Nordenstadt, 
Germany) served as loading control. Secondary antibodies were 
purchased from Dianova (Hamburg, Germany), and bands were 
detected with the ChemiDoc system (Bio-Rad, Munich, Germany). 
Quantification was performed using the ImageLab software (Bio-
Rad, Munich, Germany).
Immunohistochemistry
Four-micrometer slices of perfusion-fixed (3% para-
formaldehyde) paraffin embedded kidneys were stained for 
PKGI (Geiselhöringer et al., 2004), renin [either chicken anti-
renin (Machura et al., 2009) or goat anti-renin (R&D systems, 
Wiesbaden-Nordenstadt, Germany)] or α-smooth muscle actin 
(α-SMA; Beckman Coulter, Germany). Secondary fluorophore-
coupled antibodies were obtained from Dianova, Hamburg, 
Germany. Fluorescence was detected using an Axiovert 200 
microscope (objective: 20x; Zeiss, Jena, Germany) and analyzed 
using the axiovision software. Kidneys from at least three different 
Regulation of Renin by PKGSchramm et al.
4 July 2019 | Volume 10 | Article 800Frontiers in Pharmacology | www.frontiersin.org
animals were stained per treatment, whereof one representative 
staining is shown.
Plasma Renin Concentration
For the determination of renin concentration in plasma 
by ELISA (Angiotensin I (PRA) ELISA; DB52011: IBL 
International, Germany), blood was drawn either from the 
fascial vein or from the retrobulbar plexus under isoflurane 
anesthesia. Following centrifugation (2,000×g, 20 min), plasma 
was stored at −80°C until further processing. Alternatively, 
venous perfusate obtained from isolated perfused kidneys was 
centrifuged at 1,500×g for 10 min and stored at –20°C. For 
the determination of renin concentration, plasma was diluted 
1:10–1:1,000 (depending on treatment) with maleic acid buffer 
(33.5 mM TRIS, 50 mM maleic acid, 10 mM EDTA; pH = 6.0) 
to a final volume of 100 µl and 1 µl PMSF (kit content), 40 µl 
renin substrate (= plasma from bilaterally nephrectomized male 
rats), as well as 15 µl generation buffer (kit content) was added. 
Samples were then divided into three fractions, whereas one 
part was incubated at 4°C for 90 min and the other two parts as 
duplicate at 37°C for 90 min. Continuation followed according 
to the manufacturer. Calculation of results was also performed 
following manufacturer’s recommendation: (value mean − blank 
value) × 0.74.
Statistical Analysis
All data are expressed as mean ± SEM, whereas N, as indicated 
in figures, represents biological replicates. The sample size was 
determined using the G-power 3.1 program. Calculation of 
statistical differences was performed using GraphPad Prism 5. For 
the calculation of significant differences between different means, 
one-way analysis of variance (ANOVA) followed by Bonferroni 
posttest was performed. If unequal variances were calculated, 
Kruskal–Wallis test was performed followed by Dunn’s posttest. 
The levels of significance (p values) were considered as follows: 
<0.05 significant, <0.01 and <0.001 highly significant and stated 
as *, **, and *** in figures.
RESULTS
PKGI Is Expressed in the Juxtaglomerular 
Apparatus and Can be Deleted Selectively
First, we validated whether our conditional knockout strategy 
worked. Therefore, we used kidneys from Ctr as well as Ren-
PKGI-KO animals and costained them with renin and PKGI 
(Figure 1). We clearly detected a costaining of PKGI and renin in 
Ctr kidneys and therefore an expression of this kinase in JG cells 
(Figure 1A, arrows indicate costaining), confirming our previous 
results (Schinner et al., 2013). In contrast, in mice lacking PKGI 
in the JG cells due to an expression of Cre recombinase under 
the Renin1d promotor, we did not observe any colocalization 
of PKGI and renin anymore (Figure 1B, arrows indicate absent 
costaining), whereas expression of PKGI in arterioles was not 
influenced. Hence, we conclude that Ren-PKGI-KO animals are 
a suitable model for studying PKGI actions in JG cells.
PKGI Is Not Chiefly Involved in the Chronic 
Regulation of Renin Synthesis, Secretion, 
or Recruitment Following Different Salt 
Diets
Next, we challenged the RAAS in these mice via stimulation (low 
salt, LS; low salt + enalapril, LS/Ena) or inhibition (high salt, HS) 
of renin synthesis. At first, we measured systolic blood pressure 
FIGURE 1 | Validation of knockout strategy: Immunohistochemical costainings from kidneys of (A) Ctr and (B) Ren-PKGI-KO animals. Red: PKGI; yellow: renin. 
Arrows indicate either (A) costaining or (B) absent expression in the JGA. G, glomerulus.
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(SBP) in conscious animals via tail cuff plethysmography 
(Supplemental Table 1). We did not detect any differences 
during a normal salt diet between genotypes. Following 3 weeks 
of LS/Ena treatment, SBP of control animals was significantly 
lowered to 75% of the base value, as expected. However, SBP 
of Ren-PKGI-KO mice also dropped but interestingly not as 
pronounced as in the controls (87% of base value, significant 
difference vs. control).
Immunohistochemistry (IHC) images of Ctr animals 
(Figure 2A–D) showed a clear upregulation of renin expression 
following LS treatment, which was even more pronounced in 
LS/Ena-treated mice, concordant with the abolished negative 
feedback control of AngII upon angiotensin conversion enzyme 
(ACE) blockade. Inhibition of renin synthesis by HS resulted 
in a slight downregulation of renin. In Ren-PKGI-KO animals 
(Figure 2E–H), apparently, the same changes in renin expression 
were detected. Regarding renin recruitment following LS/Ena 
treatment, no differences occurred between the two genotypes. 
We noticed a transformation of preglomerular vascular smooth 
muscle cells to renin-producing cells (Figure 2C and G compared 
to A and E) and hypertrophy of juxtaglomerular cells, resulting 
in the so-called cuff-like structures around the glomerulus in 
both genotypes (Supplemental Figure 1).
To quantify our observations, we performed mRNA and 
protein analysis from kidney tissue and determined PRC. 
Regarding renin mRNA (Figure 3A), an about twofold 
upregulation was detected in both genotypes following LS 
treatment. Under additional ACE inhibition, control animals 
further enhanced renin-mRNA generation about ninefold to NS 
treatment, this upregulation was abolished in mice lacking PKGI 
in JG cells. Following HS treatment, both genotypes had renal 
renin mRNA levels comparable to NS-treated animals.
Since mRNA levels of renin were highly significantly 
altered after LS/Ena treatment, we were also interested if this 
difference was also reflected in renal renin protein content. 
However, both genotypes responded similarly with an about 
twofold upregulation of protein upon LS/Ena stimulation as 
assessed via quantitative Western blot (Figure 3B). Moreover, 
renin protein amounts following LS and HS treatments also 
did not differ between both genotypes as already implied by 
mRNA levels (data not shown). Considering that an altered 
electrolyte handling induced by different salt diets might also 
cause an adapted renal expression of the PKGs, we estimated the 
protein concentrations of PKGIα and PKGII via Western blot 
(Supplemental Figure 2). We did not detect an obvious change 
in expression of neither PKG isoform indicating that, at least in 
the murine kidney, different salt loads do not lead to a modified 
protein concentration of PKG.
We also analyzed PRC (Figure 3C) via ELISA. By LS 
treatment, PRC was enhanced in both genotypes to a similar 
extent compared to NS. Additional treatment with enalapril 
further exceeded PRC in both genotypes, comparable to the 
FIGURE 2 | Immunohistochemical analysis of the juxtaglomerular apparatus (JGA) during different salt loads: Representative costainings of renin (yellow) and 
α-smooth muscle actin (α-SMA, turquoise). (A–D) Ctr; (E–H) Ren-PKGI-KO. (A, E) normal salt (NS); (B, F) low salt (LS); (C, G) low salt + enalapril (LS/Ena);  
(D, H) high salt (HS). Stainings were repeated at least three times from different animals. G, glomerulus. 
Regulation of Renin by PKGSchramm et al.
6 July 2019 | Volume 10 | Article 800Frontiers in Pharmacology | www.frontiersin.org
enhancement seen in mRNA levels. Inhibition of the RAAS by 
high salt diminished PRC between 10% (Ren-Cre/PKGI fl/fl) and 
20% (PKGI fl/fl) compared to normal salt conditions.
Knockout of Both Expressed PKG 
Isoforms Also Does Not Influence Chronic 
Renin Regulation
Since both PKGIα and PKGII are expressed in JG cells 
(Gambaryan et al., 1996; Wagner et al., 1998; Schinner et al., 
2013) we considered, if a lack of PKGI was compensated by 
PKGII, therefore, an involvement of PKGI in renin regulation 
could be masked by the presence of the other kinase. Hence, we 
mated the aforementioned mice with mice carrying a PKGII null 
mutation (PKGII-KO) and reanalyzed these animals by applying 
NS and LS/Ena diets, whereby animals which did not contain the 
Cre recombinase (PKGII-KO) served as controls (Figure 4A–G). 
Again, we observed an upregulation of renin mRNA following 
LS/Ena treatment (Figure 4E) especially in mice where only 
PKGII was deleted (PKGII-KO). In double-knockout animals 
(Ren-PKGI-KOPKGII-KO), the increase in renin mRNA was 
not as pronounced as in single PKGII-KOs without reaching 
statistical significance. This trend was continued in protein 
levels, since double KOs tended to have a somewhat lower renin 
protein concentration following LS/Ena treatment as assessed 
qualitatively via IHC (Figure 4B and D) and quantitatively via 
Western blot (Figure 4F). However, when analyzing PRC (Figure 
4G), we detected an LS/Ena-dependent upregulation in single as 
well as in double Kos, while the aforementioned differences were 
not observed anymore.
Prolonged Stimulation of Soluble 
Guanylate Cyclase Leads to Recruitment 
of Preglomerular Renin Cell Precursors to 
Renin-Expressing Cells Independently of 
PKG
As a previous study demonstrated that sGC is responsible for 
renin recruitment during LS/Ena treatment, we wondered if 
we could cause recruitment in normal salt treated animals by 
applying the sGC stimulator Bay 41-8543. At first, we confirmed 
the expression of sGC (subunit β1) in juxtaglomerular cells of all 
genotypes by IHC stainings costained with renin (Supplemental 
Figure 3A–D). We also validated whether the genetic knockout 
of PKGs in these animals itself leads to an altered sGC regulation 
without any further manipulation (Supplemental Figure 3E, F). 
By analyzing mRNA and protein contents of whole kidney 
homogenates, we did not detect any difference in the expression 
levels of sGCβ1 between the different genotypes, suggesting that 
sGC expression is not altered when one or both PKG isoforms 
are absent. Since it is known that Bay 41-8543 can decrease 
blood pressure significantly (Stasch et al., 2002), we assured that 
the applied dose did not induce a decrease in blood pressure 
(Supplemental Table 1). SBP remained stable before and after 
1 week of a once daily i.p. treatment with 1 mg/kg Bay 41-8543, 
suggesting that possible changes in renin regulation after this time 
period are not a consequence of altered blood pressure but of a 
direct effect. We then treated animals either with vehicle or with 
Bay 41-8543 (1 week, 1 mg/kg i.p., once daily) and analyzed renin 
recruitment by costainings of renin and α-SMA (Figure 5A–H). 
Upon sGC stimulation, we observed occasionally occurring 
FIGURE 3 | Renin mRNA, renin protein and plasma renin concentration (PRC) during different salt loads: (A) renal renin mRNA, relative quantification calculated 
per ΔΔCt compared to normal salt treated animals of the same genotype. (B) representative Western blot and relative quantification concerning renal renin 
protein content. Western blot was loaded with 70 µg protein/lane and incubated with anti-vinculin (116 kDa) as loading control and anti-renin (44–36 kDa). Lane 
1: Ctr, normal salt; lane 2: Ctr, low salt + enalapril; lane 3: Ren-PKGI-KO, normal salt; lane 4: Ren-PKGI-KO, low salt + enalapril. Statistical analysis shows relative 
expression of renin normalized to vinculin following LS/Ena compared to normal salt treated animals of the same genotype. *,**: (highly) significant difference 
(Kruskal–Wallis test). (C) relative PRC compared to normal salt treated animals. ***: highly significant difference between LS/Ena-treated mice of different genotypes 
(ANOVA, p < 0.001).
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renin-positive cells located distally from the juxtaglomerular 
apparatus (JGA), confirming the suggested role of sGC for renin 
recruitment (Figure 5E–H, arrows indicate renin-positive cells), 
although the majority of JG cells showed a staining similar to 
vehicle-treated animals (an example of a nonrecruited JGA for 
each genotype is shown in Supplemental Figure 4). This effect 
was not mediated by PKGs, as all genotypes responded similarly. 
Neither renin mRNA nor overall kidney renin protein content 
was altered following prolonged sGC stimulation compared to 
vehicle-treated animals in any genotype (Figure 5I, J), which 
also was reflected by unchanged PRC levels (Figure 5K). Since 
administration of drugs can lead to altered expression levels of 
the targeted protein, we examined renal sGC-mRNA and protein 
content (supplemental Figure 5A, B). We did not observe any 
differences in neither genotype of Bay 41-8543-treated animals 
compared to vehicle-treated animals, indicating that Bay 41-8543 
did not influence transcriptional or translational processes of 
sGC. We also controlled systolic blood pressure before and 
7  days after Bay 41-8543 treatment in Ctr and Ren-PKGI-KO 
mice (Supplemental Table 1). However, we did not detect any 
differences, which suggests that 1 mg/kg of the sGC stimulator 
does not induce any lasting decrease in blood pressure.
Acute Stimulation of Soluble Guanylate 
Cyclase Leads to an Enhanced Renin 
Secretion Which is Abolished When PKG 
is Missing
We were not only interested in chronic effects of Bay 41-8543 
but also if an acute treatment altered renin regulation. Initially, 
we used the model of the isolated perfused kidney (IPN), which 
enables the measurement of perfusate flow and secreted renin 
directly after the perfusate passed the kidney. We analyzed both 
parameters in kidneys of all genotypes after adding increasing 
concentrations of Bay 41-8543 to the perfusate (10 nM, 100 nM, 
1 µM). Regarding perfusate flow (Figure 6A), we ended up by 
FIGURE 4 | Renin analysis of double knockouts during NS and LS/Ena treatment: (A–D) representative costainings of renin (yellow) and α-smooth muscle actin 
(α-SMA, turquoise). (A, B) PKGII-KO; (C, D) Ren-PKGI-KO/PKGII-KO. (A, C) normal salt; (B, D) low salt + enalapril; stainings were repeated at least three times from 
different animals. G, glomerulus. (E) renal renin mRNA, relative quantification of LS/Ena treatment calculated per ΔΔCt compared to normal salt treated animals of 
the same genotype. (F) representative Western blot and relative quantification concerning renal renin protein content. Western blot was loaded with 70 µg protein/
lane and incubated with anti-vinculin (116 kDa) as loading control and anti-renin (44–36 kDa). Lane 1: PKGII-KO, normal salt; lane 2: PKGII-KO, low salt + enalapril; 
lane 3: Ren-PKGI-KO/PKGII-KO, normal salt; lane 4: Ren-PKGI-KO/PKGII-KO, low salt + enalapril. Statistical analysis shows relative expression of renin upon LS/Ena 
treatment compared to normal salt treated animals of the same genotype. (G) relative plasma renin concentration compared to normal salt treated animals.
Regulation of Renin by PKGSchramm et al.
8 July 2019 | Volume 10 | Article 800Frontiers in Pharmacology | www.frontiersin.org
FIGURE 5 | Renin analysis after chronic soluble guanylate cyclase (sGC) stimulation: Mice were treated either with vehicle or with Bay 41-8543 (1 mg/kg BW) via 
intraperitoneal injection once a day for 1 week. (A–H) representative costainings of renin (yellow) and α-smooth muscle actin (α-SMA, turquoise); vehicle-treated 
mice: (A–D) Bay-treated mice; (E–H) (A, E) Ctr; (B, F) Ren-PKGI-KO; (C, G) PKGII-KO; (D, H) Ren-PKGI-KO/PKGII-KO. Stainings were repeated at least three 
times from different animals. Arrows indicate recruited renin-expressing cells following Bay treatment. G, glomerulus. (I) renal renin mRNA, relative quantification 
calculated per ΔΔCt compared to vehicle-treated animals of the same genotype (Kruskal–Wallis test). (J) representative Western blot and relative quantification 
concerning renal renin protein content. Western blot was loaded with 70 µg protein/lane and incubated with anti-vinculin (116 kDa) as loading control and anti-renin 
(44–36 kDa). Lane 1: Ctr, vehicle-treated; lane 2: Ctr, Bay-treated; lane 3: Ren-PKGI-KO, vehicle-treated; lane 4: Ren-PKGI-KO, Bay-treated; lane 5: PKGII-KO, 
vehicle-treated; lane 6: PKGII-KO, Bay-treated; lane 7: Ren-PKGI -KO/PKGII-KO, vehicle-treated; lane 8: Ren-PKGI-KO/PKGII-KO, Bay-treated. Statistical analysis 
shows relative expression of renin compared to vehicle-treated animals of the same genotype (Kruskal–Wallis test). (K) relative plasma renin concentration compared 
to vehicle-treated animals of the same genotype.
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adding 10 µM of the NO-donor SNAP (S-Nitroso-N-acetyl-D,L-
penicillamine; positive control). In kidneys of control animals 
(Ctr), we detected an increase in perfusate flow following 
increasing Bay 41-8543 concentrations, which could be slightly 
enhanced by the final addition of SNAP. In contrast, in kidneys 
from mice lacking either one or both PKG isoforms, this 
effect was less pronounced with the strongest (and statistically 
significant) difference in kidneys of double-knockout mice [18% 
increase, compared to control (37% increase)]. To study and 
evaluate the efficiency of an sGC stimulation on renin secretion, 
we studied the renin concentration found in the perfusate 
following Bay 41-8543 and SNAP treatment (Figure 6B). While 
10 nM Bay 41-8543 had no effect on renin release rate, 100 nM 
Bay 41-8543 induced a moderate renin secretion, and 1 µM Bay 
41-8543 caused a marked increase (approximately fourfold of 
nontreated) in kidneys of control animals (Ctr, white bars). The 
final stimulation with SNAP led to a slightly further enhanced 
renin release. When we analyzed kidneys of Ren-PKGI-KO 
animals (light gray bars), we detected quite similar increases 
in renin release compared to control animals. Kidneys of 
PKGII-KO (dark gray bars) also reacted with a clear increase in 
renin release upon Bay stimulation. However, renin release upon 
SNAP infusion was even more prominent (more than doubled) 
in kidneys of these animals compared to SNAP-infused kidneys 
of control animals. In contrast, kidneys of double-knockout 
animals (Ren-PKGI-KO/PKGII-KO, black bars) did not respond 
at all on Bay 41-8543, and the impact of SNAP was substantially 
diminished compared to control animals. Since we could not 
be sure if these kidneys in general reacted with a reduced renin 
release, we finally also infused isoproterenol, an inductor known 
to cause a strong renin release. However, both kidneys of control 
animals and kidneys of double-knockout animals increased 
renin release similarly in response to isoproterenol stimulation 
[713 vs. 900 ng angI/(h ml) per g kidney weight, data not shown].
Since the IPN is an ex vivo model, we finally wanted to 
investigate if these effects were also seen in vivo. Therefore, 
we applied Bay 41-8543 i.p. to animals of all genotypes and 
determined the PRC 45 min postinjection (Figure 7A). In 
control animals as well as in both single knockouts, the PRC was 
more than doubled compared to that in vehicle-treated animals 
of the same genotype. However, double-knockout animals almost 
completely failed to respond to the Bay injection; we detected 
only a slight and nonsignificant increase in PRC compared 
to vehicle-treated mice. In contrast, the difference upon Bay 
stimulation between Ctr control animals and Ren-PKGI-KO/
PKGII-KO double knockouts reached statistical significance 
FIGURE 6 | Effect of sGC-stimulation on renin secretion rate in the isolated perfused kidney: Isolated perfused kidneys of either genotype were treated with 
increasing concentrations of Bay 41-8543 (10 nM–1 µM) followed by the NO-donor SNAP (10 µM) as positive control. (A) Perfusate flow of isolated perfused 
kidneys of Ctr (control, white circle), Ren-PKGI-KO (black circle), PKGII-KO (black triangle), or Ren-PKGI-KO/PKGII-KO (black square). Data are presented as 
mean ± SEM of all animals of the same genotype at each time point. *,***: (highly) significant difference between 1 µM Bay- or SNAP-treated kidneys of Ctr vs. Ren-
PKGI-KO/PKGII-KO (t test, p < 0.05 for *, p < 0.001 for ***). (B) Renin secretion rate of isolated perfused kidneys of Ctr (white), Ren-PKGI-KO (light gray), PKGII-KO 
(dark gray), or Ren-PKGI-KO/PKGII-KO (black). ***: highly significant difference between Bay-treated kidneys of Ctr vs. Ren-PKGI-KO/PKGII-KO as indicated 
(ANOVA, p < 0.001).
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(p < 0.05), hence reflecting the previously obtained results in the 
IPN experiments.
Considering that blood pressure is a crucial regulator of 
renin secretion, we supposed that a varying blood pressure 
response to Bay 41-8543 in the four genotypes might account 
for the differences seen in PRC. Hence, we analyzed systolic 
blood pressure (SBP) after an acute treatment with Bay 41-8543 
compared to vehicle treatment (Figure 7B). As expected, SBP 
dropped slightly, however nonsignificantly following sGC 
stimulation in accordance to the vasodilating effect of cGMP. 
Importantly, this effect was observed in all genotypes, indicating 
that blood pressure differences were not responsible for the 
effects on PRCs. Moreover, sGC expression was not altered by the 
genetic manipulations in the different genotypes (Supplemental 
Figure 3), excluding that different levels of sGC led to a varying 
response to Bay 41-8543. Therefore, we conclude that the acute 
effects seen on PRC are dependent of PKGs.
DISCUSSION
In this study we have examined renin regulation by cGMP/
PKG. For these studies, we used single- and double-knockout 
mice of renin-cell-specific PKGI-KO and of total PKGII-KO 
under basal and renin–angiotensin–aldosterone system (RAAS)-
stimulating and -inhibiting conditions. Furthermore, we studied 
cGMP effects upon sGC stimulation in these animals and in 
isolated perfused kidneys (IPN). Thereby, we have shown that 
cGMP/PKG does not alter chronic renin balance regarding renin 
release and recruitment but is involved in acute changes of renin 
secretion.
As stated above, basal renin regulation and chronic stimulation 
of the RAAS was not changed upon PKG deletion. An obvious 
explanation is that, under these chronic conditions, NO/cGMP-
mediated effects on renin secretion and recruitment are not 
dependent on PKGs. This is in accordance to several previous 
reports which state that renin regulation is chiefly controlled 
by the cAMP/protein kinase A (PKA) system. Importantly, 
phosphodiesterases (PDEs) allow a crosstalk between the cGMP 
and the cAMP system. NO/cGMP-mediated regulation of renin 
responses is thought to be mainly controlled by PDE3 (Schweda 
and Kurtz, 2004). This PDE isoform is inhibited by cGMP but has 
a substrate specificity for both cGMP and cAMP, thus enabling 
an increase in cAMP following cGMP binding and subsequent 
PKA activation. Several previous reports stated that cGMP 
crosstalk via PDE3-mediated cAMP rise is responsible for the 
stimulation of renin secretion (summarized in Szaszák et al., 
2008). Another explanation could be that counter regulations 
regarding adrenal release of aldosterone might mask cGMP-
specific effects. PKGI and PKGII were found to be expressed 
in the adrenal gland. Previous studies have shown that PKGII 
is expressed in the zona glomerulosa. It was reported that basal 
aldosterone release is involved by PKGII in isolated rat zona 
glomerulosa cells (Gambaryan et al., 2003). However, murine 
PKGII deletion did not change aldosterone release under basal 
conditions and upon LS treatment (Spiessberger et al., 2009). The 
role of PKGI in the adrenal gland is uncertain. Ren1d expression 
was previously found in fetal adrenal gland (Fabian et al., 1989), 
but its expression was not revealed in the adult adrenal gland. 
Therefore, we performed IHC stainings to validate whether 
PKGI is deleted in the adrenal gland of the Ren-PKGI-KO mice 
(data not shown). We did not detect a deletion of PKGI but 
could endorse the previous studies by Gambaryan et al. that 
PKGI is only expressed in the capsule and blood vessels but 
not found in the zona glomerulosa (Gambaryan et al., 2003). 
Moreover, aldosterone serum concentrations were not altered 
between Ctr and Ren-PKGI-KO animals, at least under control 
conditions (data not shown). Hence, it can be assumed that 
counter regulations by aldosterone did not mask any effects on 
renin regulation. Furthermore, the acute changes in IPN argue 
FIGURE 7 | Renin analysis 45 min after sGC stimulation: Mice were treated either with vehicle or with Bay 41-8543 (1 mg/kg BW) via intraperitoneal injection 
for 45 min. Data are presented as mean ± SEM. (A) plasma renin concentration of vehicle vs. Bay-treated animals of different genotypes. *,**: (highly) significant 
difference either between Ctr vehicle-treated vs. Bay-treated or between Ctr Bay-treated vs. Ren-PKGI-KO/PKGII-KO Bay-treated (ANOVA, p < 0.05 for *, p < 0.01 
for **). (B) systolic blood pressure (SBP) of vehicle (white bars) vs. Bay-treated animals (squared bars). SBP was determined via tail cuff plethysmography, whereas 
mice were trained for three to four consecutive days prior to measurement. Three to ten measurements/animal were averaged. 
Regulation of Renin by PKGSchramm et al.
11 July 2019 | Volume 10 | Article 800Frontiers in Pharmacology | www.frontiersin.org
for kidney-specific effects of PKGs. It should be noted that we 
observed significant differences regarding renin mRNA level 
following LS/Ena treatment, preferentially in animals, where 
PKGI was missing in the JG cell (Ren-PKGI-KO and Ren-
PKGI-KO/PKG II-KO, Figures 3A and 4E). Some recent studies 
suggest that PKGs might affect transcriptions of different genes by 
phosphorylating transcription factors (Lee et al., 2015; Ma et al., 
2016). We can only speculate that these mechanisms might also 
lead to a diminished renin transcription. However, since renal 
renin protein as well as PRCs remained unaltered compared to 
control animals, this finding seems to be of minor importance in 
terms of overall renin regulation.
Contradictory data have been published regarding the impact 
of the cGMP system on renin regulation (Hofmann et al., 2006). 
Most reports support the view that cGMP decreases RAAS 
activity. Previous reports suggested that cGMP-activated PKGII 
and possibly PKGI inhibit renin secretion (Gambaryan et al., 
1998; Wagner et al., 1998). However, these experiments were 
performed mainly in isolated juxtaglomerular cells. Therefore, 
it might be that, upon culturing, these cells altered their 
differentiation status so that these conditions are not comparable 
to other studies.
Our results confirm that positioning of renin-secreting cells 
upon enalapril/low salt treatment is dependent on NO-GC 
(Neubauer et al., 2013). Interestingly, renin recruitment was 
not changed upon deletion of PKGI and II. Hence, these results 
indicate that renin recruitment under chronic conditions is 
dependent on cGMP, but is PKG independent.
Our results indicate that PKG enzymes are involved in acute 
renin secretion. In our experiments of IPN and of acutely Bay-
treated animals, renin release, which was enhanced by Bay 
application, was strongly affected by the deletion of both kinases. 
These results suggest that stimulation of renin secretion by 
cGMP is mediated by PKGI and II. Interestingly, PKGII deletion 
alone had a stronger effect on renin secretion than single renin-
cell-specific deletion of PKGI. Therefore, it can be concluded that 
PKGII is more strongly involved in this stimulatory effect of BAY 
on renin release than PKGI. In contrast, application of SNAP lead 
to a strong stimulatory effect in PKGII-KO mice This indicates 
that, at high NO concentrations, PKGII might exhibit inhibitory 
effects on renin secretion. Neubauer et al. previously have shown 
using Ren1d+/Cre–NO-GCfl/fl kidneys that application of the 
NO-donor sodium nitroprusside (SNP) enhanced perfusate flow 
and that this effect was dependent on the presence of NO-GC 
in renin-expressing cells (Neubauer et al., 2013). Previously, it 
was shown that the application of NO donors enhanced perfusate 
flow of isolated rat kidney. It was suggested that cGMP inhibition 
of PDE3 mediated these effects (Kurtz et al., 1998). In our studies, 
the application of the sGC stimulator Bay-41-8543 also enhanced 
the perfusate flow. Deletion of total PKGII or renin-cell-specific 
PKGI alone did not significantly alter Bay-mediated stimulation 
of perfusate flow. However, this outcome was absent in the 
double knockout, suggesting that both PKG enzymes, PKGI and 
II, are involved in perfusate flow. Hence, the effect of the double-
knockout indicates that PKG enzymes compensate each other 
regarding renin secretion. An altered expression of sGC in these 
animals was not found and therefore cannot be the reason for 
this effect. It might be argued that, in these mice, a vasodilation 
which is normally induced by sGC-generated cGMP is missing. 
This could be responsible for the observations on perfusate flow, 
as expression of the Renin1d promotor using Renin1d-GFP 
reporter was previously shown in isolated microvessels (Pentz 
et al., 2001). Furthermore, in Ren1d+/Cre–NO-GCfl/fl mice, 
the NO-GC protein vanished in preglomerular smooth muscle 
cells in line with studies which demonstrated that preglomerular 
smooth muscle cells are derived from renin-expressing cells 
(Neubauer et al., 2013). However, our immunohistochemical 
analysis did not show a deletion of PKGI in the preglomerular 
vessels of the Renin-Cre-specific PKGI knockout. Furthermore, 
PKGII was previously found in juxtaglomerular cells and in 
afferent arterioles (Gambaryan et al., 1996). Therefore, altered 
perfusate flow in the double knockout cannot be excluded by a 
reduced dilative response upon PKGII deletion. However, this is 
unlikely as no effect on perfusate flow was observed in the single 
total PKGII-KO. Furthermore, there is no evidence that PKGII 
is involved in vascular smooth muscle contractility, and there 
were no effects of PKGII deletion on blood pressure observed. 
Additionally, blood pressure was nonsignificantly changed by 
BAY application, excluding that BAY-mediated vasodilation was 
a main cause for the observed effects on renin secretion.
Others demonstrate that NO/cGMP can also acutely increase 
PRC. In humans, it has been shown that an inhibition of the 
inducible NO-synthase (iNOS) by asymmetric dimethylarginine 
(ADMA) and hence diminished cGMP concentrations leads to a 
decrease in PRC (Kielstein et al., 2004). However, as renovascular 
resistance was enhanced simultaneously by the administration of 
ADMA, the observed decrease in PRC might be a consequence of 
altered hemodynamics as well. In contrast, a recent study by Chen 
et al. suggests that acute activation of the particulate guanylyl-
cyclase A receptor and hence enhancement of cGMP leads to 
a decrease in plasma renin activity (Chen et al., 2018). Since 
these studies were performed in anesthetized dogs, differences 
regarding the used model organism as well as consciousness of 
the animals have to be taken into consideration.
Next, it would be interesting to elucidate which mechanisms 
and substrates of PKGI and/or PKGII are mediating the acute 
stimulation of renin secretion. In several organs, it was shown that 
PKGI reduces intracellular calcium concentrations. Therefore, it 
might be conceivable that this effect is also found in the renin-
secreting cells. Previous studies reported juxtaglomerular cells 
exhibit the calcium paradoxon, which means that calcium 
reduction leads to enhanced renin secretion. This mechanism 
might be also due for the PKGI-mediated renin secretion. Recent 
results have shown that a mechanism of the calcium paradoxon 
involves activation of MLCK (Steppan et al., 2018). Therefore, 
it might be possible that PKGI-mediated renin secretion acts 
similarly. The mechanism of PKGII can only be speculated. 
PKGII is membrane bound and involved in secretory processes 
(Pfeifer et al., 1996; Schramm et al., 2014). In this regard, it might 
be interesting that cAMP-induced renin release was correlated 
with SNAP23-mediated exocytosis (Mendez and Gaisano, 
2013). Furthermore, the exocytosis of renin-containing granular 
organelles upon isoproterenol stimulation was shown with high 
resolution using TIRF microscopy (Buckley et al., 2017). It might 
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be that also cGMP/PKGII enhances exocytotic mechanisms 
for renin containing granules, and it would be tempting to 
analyze this process in the future. It remains to be elucidated 
why chronical and acute effects of cGMP/PKG differ. It can be 
speculated that compensatory mechanisms, e.g., regulation of 
PDEs might be the reason for these different responses.
In summary, our study indicates that cGMP/PKG does not 
induce a change in long-term regulation of renin generation 
and secretion. Under prolonged stimulation of sGC, renin 
recruitment is enhanced, an effect independent of PKG. In 
contrast, when sGC was acutely stimulated, renin secretion was 
significantly enhanced dependent on the presence of PKG. These 
results can be relevant during chronic or acute pharmacological 
application of cGMP-elevating drugs, e.g., PDE5 inhibitors or 
sGC stimulators (Krishnan et al., 2018).
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